Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04282187
Title Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington

myeloproliferative neoplasm

essential thrombocythemia

myelodysplastic/myeloproliferative neoplasm


polycythemia vera


Decitabine + Fedratinib

Decitabine + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from for the field